A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of the t op 20 translational researchers by
Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases Completed rebranding to Sio Gene Therapies as part of corporate transformation aligning corporate structure and governance with current and future business
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 NEW YORK , Nov.
AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseases Represents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Patient-level data in cohort 2 of SUNRISE-PD study demonstrates consistent, clinically meaningful outcomes and evidence of dose response Delays in manufacturing process expected to postpone the start of enrollment in randomized, controlled study Virtual R&D Day webcast on October 30 th at 11:30 AM
Agenda to feature presentations from leading clinical researchers in Parkinson’s disease and the Michael J. Fox Foundation Individual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study to be shared NEW YORK , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
NEW YORK , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has received Rare Pediatric Disease Designation from the U.S.
Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020 NEW YORK , Oct. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has received
Kristiina Vuori , M.D., Ph.D. is a leading genetics and cancer researcher who serves as President and Board member of Sanford Burnham Prebys Medical Discovery Institute A ppointment of Dr. Vuori establishes a majority independent Board of Directors Parag V.
• AXO-Lenti-PD was well-tolerated with no treatment - related serious adverse events at 6 months • 2 1- point mean improvement i n UPDRS Part III “OFF” score, a 40 % improvement from baseline , exceeding pre-defined criteria for success • Greater than 2-hour improvement from baseline in both
